FHTX vs HSIC · rev $19.3M vs P/E 24, rev $6.83B
Foghorn Therapeutics Inc (FHTX) versus Henry Schein Inc (HSIC) — a side-by-side from cached financials, not a winner call.
Foghorn Therapeutics Inc (FHTX) is a biotechnology company listed on NASDAQ.
Henry Schein Inc (HSIC) is a medical distribution company listed on NASDAQ.
Latest reported FHTX revenue for 2026-06-30 was $19.3M. Net income was -$27.1M. FHTX currently screens at market cap $237.8M.
Latest reported HSIC revenue for 2026-06-27 was $6.83B. Net income was $201.0M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
FHTX currently screens at market cap $237.8M. HSIC currently screens at market cap $9.11B and trailing P/E 24.2.
Not investment advice. Open the FHTX and HSIC stock pages for the full models.
Not investment advice.